OClawVPS.com
Larimar Therapeutics Inc.
Edit

Larimar Therapeutics Inc.

http://www.larimartx.com/
Last activity: 24.03.2025
Active
Categories: BioTechDeliveryDesignInformationPlatformResearch
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Followers
1.42K
Mentions
24
Location: United States, Pennsylvania, Lower Merion Township
Employees: 11-50
Founded date: 2016
LinkedIn
Email

Investors 1

Mentions in press and media 24

DateTitleDescription
24.03.2025Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval FDA recommended measuring skin FXN ...
11.03.2024Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s AtaxiaStudy will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin data and safety data from the OLE study are intended to help support a potential Biologi...
11.03.2024Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia-
06.03.2024Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference-
11.08.2022Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial ResultsLarimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022 In conjunction with the complete response, Larimar is proposing a Phase 2, four-week dose exploration study in Friedreich’s ataxia (FA) pat...
19.05.2022Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders CongressBALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the ...
12.05.2022Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results- CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022 - Cash at March 31, 2022 of $62.6 million provides projected cash runway in...
25.03.2022Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial ResultsBALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its full year 2021...
15.02.2022Larimar Therapeutics : Provides Update on CTI-1601 Clinical Program - Form 8-KLarimar Therapeutics Provides Update on CTI-1601 Clinical Program Bala Cynwyd, PA, February 14, 2022 - Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments ...
15.02.2022Larimar Therapeutics Provides Update on CTI-1601 Clinical ProgramBALA CYNWYD, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has receiv...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In